Cytiva Stream Recent Events/Webinars

  1. Introducing New Technology To A Multi-Specific Antibody Line 8/9/2023

    Bayer Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses audience questions on introducing new purification technologies and multi-column chromatography to multi-specific mAb processing environments in this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline.

  2. Challenges To Developing High Concentration Formulation For Multi-Specific Antibodies 8/9/2023

    During the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., answered audience questions on overcoming challenges in high-concentration antibody formulations, while simultaneously maintaining purity.

  3. Legal & Compliance Impact On Speed In The Antibody Market 8/9/2023

    In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses questions on regulatory impacts on multi-specific antibodies’ path to market, and how biopharma legal and compliance professionals can expedite the journey.

  4. PAT In Multi-Specific Antibody Manufacturing 8/9/2023

    During the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., offered advice on the role of process analytical technologies and continuous processes in multi-specific antibody production, with a focus on achieving steady-state conditions.

  5. Purification Strategies For New Classes Of Antibodies 8/9/2023

    In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses an audience question concerning purification strategies in the growing multi-specific antibody field.

  6. Maintaining Downstream Quality In Multi-Specific Antibody Manufacturing 8/9/2023

    Bayer Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses audience questions on downstream multi-specific mAb processing challenges, specifically purification in terms of CPP and QRA, and microbial or thermal degradation, in this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline.

  7. Multi-Specific Antibody Development: What Challenges The Need For Speed? 8/9/2023

    In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses why the industry is pursuing faster, more cost-effective multi-specific antibody development and some of the major challenges standing in the way of efficiency.

  8. Process Development For A Diverse mAb Pipeline 7/18/2023

    Our latest Bioprocess Online Live virtual panel event covered process development advances in a diversifying mAb market (i.e. bi- and tri-specific) with leading experts in the field.

  9. Improving Efficiency In Upstream Process Development 7/11/2023

    Explore the latest trends in cell culture technology, tools and enablers for scale-up, strategies to accelerate cell line development, media development, raw material characterization, and more.

  10. How To Develop An Efficient Downstream Purification Process For bsAbs 5/1/2023

    Bispecific antibodies (bsAbs) have gained increasing interest in recent years. Learn how to develop an efficient downstream purification process for a cancer immunotherapy bsAb.